On October 20, Veradermics, Inc. posted an Intraday Rise of 5.26% in Regular Trading, trading at $128.475 per share, with turnover of $46.3702 million.
The move aligns with continued market focus on the company’s lead candidate VDPHL01 and its cash position. Recent public updates indicated VDPHL01 met all primary and key secondary endpoints in a male pattern hair loss phase 2/3 trial, while a female pattern hair loss phase 2 study showed improvement in most participants after six months, with no treatment-related serious adverse events or cardiac adverse events reported.
Financially, the company previously disclosed about $819.9 million in cash and marketable securities, which management said is sufficient to fund operations through 2030. Earlier in October, the stock had already seen a sharp rally tied to the same clinical readouts, suggesting investors continue to price in both development momentum and balance-sheet support.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments